Total net revenue rose 15% to $79.9 million in the fourth quarter of 2018 compared with the fourth quarter of 2017. 1 Income before income taxes increased 25% from the fourth quarter of 2017 to $73.1 million . BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Innoviva, Inc.

First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation LONDON --(BUSINESS WIRE)--Nov. 9, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has

Total net revenue rose 26.8% to $61.7 million compared with the third quarter of 2017. Net income attributable to Innoviva stockholders increased 98.1% from the third quarter of 2017 to $47.1 million , or $0.43 per diluted share. The Company made a partial repayment of $110.0 million on its Term B

LONDON --(BUSINESS WIRE)--Sep. 21, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta

Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the second quarter of 2017 to $54.6 million , or $0.49 per diluted share. The Company intends to prepay $110 million of its Term B Loan.

Hulme to execute capital allocation review and cost cutting initiatives of the board; will also oversee investigation into conduct of advisors to the board in connection with 2017 proxy contest BRISBANE, Calif. --(BUSINESS WIRE)--May 22, 2018-- Innoviva, Inc.

Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017. Net income attributable to Innoviva stockholders increased 76% from the first quarter of 2017 to $29.6 million , or $0.29 per basic share. BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 26, 2018-- Innoviva, Inc.

LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 24, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration ( FDA ) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol

Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 18, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc.

LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 8, 2018-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled